View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 5, 2021updated 12 Jul 2022 11:29am

Medidata expands partnership with Horizon Therapeutics for trials

American technology firm Medidata, a subsidiary of Dassault Systèmes, has expanded its partnership with biopharmaceutical company Horizon Therapeutics to improve efficiencies and outcomes in clinical trials.

American technology firm Medidata, a subsidiary of Dassault Systèmes, has expanded its partnership with biopharmaceutical company Horizon Therapeutics to improve efficiencies and outcomes in clinical trials.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Under the expanded partnership, Medidata will provide a wide range of solutions for Horizon’s clinical research needs in various therapeutic areas, such as ophthalmology, rheumatology, and nephrology.

Medidata co-founder and co-CEO Tarek Sherif said: “We’re delighted to be a key partner to Horizon and its exceptional journey that benefits patients by advancing science and treatments.

“Medidata’s goal is to facilitate Horizon’s path forward using advanced analytics and technology. We’re looking forward to further supporting the company’s vision, especially as it relates to improving efficiencies and speeding the completion of clinical studies.”

Using Medidata’s most used platform, Medidata Rave Clinical Cloud, Horizon will access a broad range of clinical trial solutions.

The Medidata platform is used to accelerate clinical research with a set of applications such as data capture, data management, trial planning, as well as trial management.

Furthermore, Horizon will use Medidata’s Intelligent Trials product to bring ‘cross-industry real-time performance metrics, predictive models, and forecasting capabilities’ for clinical trial planning as well as its execution.

Built on the industry’s broadest clinical trial dataset, Intelligent Trials brings artificial intelligence (AI), partnered with advanced analytics.

It covers over six million patients in more than 22,000 clinical trials.

Horizon Therapeutics research and development executive vice-president Karin Rosén said: “Through the use of the Medidata technologies, we have been able to create a more efficient, manageable and cost-effective clinical trial process, which led us to expand this productive relationship.

“As our clinical needs have evolved, the Medidata platform gives us the flexibility and agility to scale and grow.”

In July last year, Medidata said it would support clinical trials of Moderna’s Covid-19 vaccine candidate ‘mRNA-1273’ after the companies entered a partnership.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena